NYSE:SNN - Smith & Nephew Stock Price, Forecast & News

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Smith & Nephew announced a -- dividend on Monday, September 23rd. Shareholders of record on Friday, October 4th will be paid a dividend of $0.288 per share on Wednesday, October 30th. This represents a yield of 1.5%. The ex-dividend date is Thursday, October 3rd. View Smith & Nephew's Dividend History.

Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.39 by $0.59. View Smith & Nephew's Earnings History.

Smith & Nephew is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Smith & Nephew.

Smith & Nephew issued an update on its FY 2020 IntraDay earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.344-5.395 billion.

5 Wall Street analysts have issued twelve-month price objectives for Smith & Nephew's shares. Their forecasts range from $6.00 to $52.00. On average, they anticipate Smith & Nephew's stock price to reach $29.00 in the next twelve months. This suggests that the stock has a possible downside of 42.5%. View Analyst Price Targets for Smith & Nephew.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Smith & Nephew.

Headlines about SNN stock have trended very negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Smith & Nephew earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Smith & Nephew.

Smith & Nephew saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,750,000 shares, a drop of 7.9% from the January 15th total of 1,900,000 shares. Based on an average trading volume of 592,200 shares, the days-to-cover ratio is currently 3.0 days. Currently, 0.4% of the shares of the company are sold short. View Smith & Nephew's Current Options Chain.

Some companies that are related to Smith & Nephew include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wound Management Technologies (WNDM), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), RTI Surgical (RTIX) and Invacare (IVC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), Gilead Sciences (GILD), AbbVie (ABBV), RPM International (RPM), Alibaba Group (BABA), Pfizer (PFE), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY) and CVS Health (CVS).

Smith & Nephew's stock is owned by a number of of retail and institutional investors. Top institutional investors include WCM Investment Management LLC (0.96%), Nuance Investments LLC (0.76%), Cambiar Investors LLC (0.73%), FMR LLC (0.26%), Bank of America Corp DE (0.26%) and Envestnet Asset Management Inc. (0.15%).

SNN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cambiar Investors LLC, State Street Corp, Connor Clark & Lunn Investment Management Ltd., New York State Common Retirement Fund, Jane Street Group LLC, Barclays PLC and Goldman Sachs Group Inc..

SNN stock was purchased by a variety of institutional investors in the last quarter, including Nuance Investments LLC, WCM Investment Management LLC, Envestnet Asset Management Inc., Natixis Advisors L.P., Citigroup Inc., Raymond James & Associates, M&T Bank Corp and Stifel Financial Corp.

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SNN stock can currently be purchased for approximately $50.45.

Smith & Nephew has a market capitalization of $22.06 billion and generates $4.90 billion in revenue each year. The medical equipment provider earns $663 million in net income (profit) each year or $2.02 on an earnings per share basis. Smith & Nephew employs 16,377 workers across the globe.View Additional Information About Smith & Nephew.

The official website for Smith & Nephew is http://www.smith-nephew.com/.

Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]